Insmed (NASDAQ:INSM) COO Roger Adsett Sells 2,370 Shares

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 2,370 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $242,379.90. Following the transaction, the chief operating officer owned 98,603 shares in the company, valued at $10,084,128.81. This represents a 2.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Roger Adsett also recently made the following trade(s):

• On Wednesday, April 1st, Roger Adsett sold 88,060 shares of Insmed stock. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80.

Insmed Price Performance

NASDAQ INSM opened at $94.22 on Friday. Insmed, Inc. has a 12 month low of $70.57 and a 12 month high of $212.75. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. The firm has a market capitalization of $20.42 billion, a PE ratio of -16.39 and a beta of 0.79. The company’s 50 day simple moving average is $130.45 and its 200 day simple moving average is $154.95.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. The business had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business’s revenue for the quarter was up 229.7% on a year-over-year basis. During the same quarter last year, the business earned ($1.42) earnings per share. As a group, equities research analysts forecast that Insmed, Inc. will post -2.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC grew its position in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares in the last quarter. Kingsview Wealth Management LLC grew its position in Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 60 shares in the last quarter. Choreo LLC grew its position in Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 65 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 69 shares in the last quarter. Finally, ORG Partners LLC grew its position in Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have issued reports on INSM shares. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Raymond James Financial started coverage on shares of Insmed in a research report on Friday, April 10th. They issued an “outperform” rating and a $200.00 price target on the stock. Mizuho lifted their price target on shares of Insmed from $204.00 to $206.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 25th. HC Wainwright restated a “buy” rating on shares of Insmed in a research report on Friday, May 8th. Finally, Bank of America lifted their price target on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $210.50.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.